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INTRODUCTION
Ovarian cancer is cancer with the highest prevalence in the females. National The Institutes of Health (NIH) National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) in 2016 found that 22,280 new cases of ovarian cancer 1, 2 happened in the USA. Cancer Country Profiles found that ovarian cancer was fourth cancer with the most incidence in Indonesian females with 10,238 cases in 2014. Epithelial ovarian cancer takes up to 65-70% of all ovarian cancer incidence and 90% of all 3 ovarian cancer malignancy.
Ovary epithelial cells take part in ovulation, causing injury followed by inflammation and 4 resolution. Repeated ovulation and ovary injury will cause surface epithelial cells entrapped in the ovary cortex and form small epithelial cysts. This process 3 could change into ovarian epithelial malignancy. It means that the more ovulation happens, the higher risk for ovarian epithelial malignancy. Risk factors include early menarche, late menopause, nulliparity, obese, estrogen hormone therapy, and family history of an ovary or breast cancer involving the BRCA gene. Protective factors include oral contraception, breast feeding, tubal ligation, and hysterectomy. Screening for ovarian cancer is done using ultrasound or by 6 determining tumor marker CA-125. It is not recommended for a population with no symptoms but strongly recommended for post-menopausal and older females, as more than 80% of ovarian 7 cancer is found in females aged more than 50.
CA-125 is used as a tumor marker for ovarian cancer. Use for tumor markers includes early detection and screening, diagnostic confirmation, prognosis, a prediction for therapy and disease 8 monitoring and recurrence. The rise in CA-125 level is related to malignancy such as in epithelial ovarian cancer in which 80%-85% of all cases are found with 9 an increase of CA-125 level. A physiological condition such as menstruation and pregnancy or non malignancy condition such as endometriosis, acute pancreatitis, cirrhosis, peritonitis, and pelvic inflammatory disease could also cause arise in 10 CA-125 level. Reference values mostly used for CA-125, in general, is below 35 U/mL. It is important to note that in healthy conditions, the level of CA-125 in post-menopausal females is significantly lower 11 than those in pre-menopausal females.
The use of diagnostic test is the ability to detect someone with a disease or to exclude someone without the disease, usually described by sensitivity, specificity, positive predictive value, and negative predictive value. Sensitivity and specificity are essential in measuring diagnostic test accuracy but cannot determine the probability of disease in an individual. Predictive values, on the other hand, can be used to determine the likelihood of disease in an individual, but it may vary according to disease prevalence in the population, so it is population 12 specific. This study aimed to find out the diagnostic value (sensitivity, specificity, positive predictive value, negative predictive value) of CA-125 among patients with epithelial ovarian cancer in Indonesia specifically in the Dr. Soetomo Hospital Surabaya in 2016. 
METHODS
This study was conducted in the Installation
RESULTS AND DISCUSSION
As seen in Table 1 , the age group of 20-54 years consisted of the most patients in this study 67.01% (65/97). Sattar, said that most serious or mucinous benign ovarian tumor was found in patients age 30-40 years old, meanwhile malignant ovarian tumor specific 3 was found in patients aged 45-65 years old. SEER 18 2009 SEER 18 -2013 found that the most distribution of age group was 55-64 years old (24.3%) in first place, followed by 65-74 years old (21.7%) in second place and 45-54 years old (18.5%) in the third group with a 2 median of age 63 when diagnosed. The median of age between patients in this study was 50 meaning that half of the population was diagnosed before reaching 50 years of age and the other half was diagnosed after reaching 50 years of age. Majority of patients in this study had ovarian tumor with 61.86% (60/97), as shown in Table 2 . Only 31.96% (31/97) had a benign ovarian tumor and 6.19% (6/97) with a borderline tumor. Lack of numbers of patients with a benign tumor to those with malignant tumor could be related to unspecific symptoms of ovary tumor, especially in 13 the early stage, so it was hard for patients to notice.
This condition could result in a patient delay to see a doctor. Symptoms will be noticeable in a more advanced grade such as urinary or bowel problems, pain during intercourse (dyspareunia), bleeding, and if it has spread to other organs the patient may feel 13 shortness of breath and weakness. Goff, Mandel, and Melancon found in their study that almost half of ovarian cancer patients waited three months to obtain the right diagnosis even 95% of them had felt 14 symptoms before. Benign and borderline ovary tumors can develop slowly and gradually into 3 invasive malignancies. Delays in patients to see a doctor or delays in making the right diagnosis could explain why the numbers of benign histopathological findings were less than malignant ones. decreased in productivity leading to a material loss. Endometriosis may also be a contributor in marital distress due to infertility problem. Main problems of endometriosis such as pain and infertility may cause more patients to see a doctor. Sattar stated that borderline and malignant serous types were the most common type of ovarian malignancy with 60% 3 of all ovarian malignancy. This study showed more patients with mucinous type than serous type.
Mucinous tumors tend to be larger and multicystic 3 than serous types. The recorded average size of mucinous tumors is 16-20 cm and can be very large causing urinary tract obstruction to abdominal 16 compartment syndrome. This condition may cause more severe symptoms in mucinous type than serious type resulting in patients seeing a doctor. Table 6 showed that 74.23% (72/97) patients in this study presented with CA-125 serum level above 35 U/mL, amongst them 54.64% (53/97) had malignant histopathological findings while 19.59% (19/97) had benign histopathological findings. About 25.77% (25/97) patients in this study presented with CA-125 serum level equal to or below 35 U/mL, amongst them 13.40% (13/97) had malignant histopathological findings while 12.37% (12/97) patients had benign histopathological findings. Patients with malignant histopathological findings in this study were 68.04% (66/97) while 31.96% (31/97) patients had benign histopathological findings. Sensitivity in diagnostic test measures the ability to identify subjects correctly with a specific 17 condition. As seen in Table 7 , the sensitivity of CA-125 in this study was 80.30% meaning that of ovarian malignancy cases in this study, 80.30% of were found with arise in CA-125 level above 35 U/mL. Sensitivity 80.30% was between sensitivity in studies conducted by Meier et al. (75%) and Zanaboni et al. (85%), both using second look laparotomy as the gold standard and taken from a literature review by 18 Jacobs and Bast. Specificity showed a normal level of CA-125 in those without ovarian malignancy. It measured the test ability to identify subjects 17 correctly without certain conditions. Specificity of 38.71% meant that in those without malignancy, only 38.71% had a CA-125 level below or equal to 35 U/mL, while more than 60% of them had a CA-125 level above 35 U/mL. This finding might be connected with the majority of endometriosis in benign findings with 32.26%. Several studies found that some patients with endometriosis had elevated levels of CA-125 which also correlated to the severity 18 of the disease. Menstruation and pregnancy also could cause CA-125 elevation. Haga, Sakamoto, Egami, Yoshimura, and Akagi found that CA-125 was elevated significantly in healthy females under 49 years old than in healthy females older than 18 49 years.
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Positive predictive value and negative predictive value are two primary measures to determine diagnostic accuracy. Positive predictive value is the probability that there is a disease condition in a 82%. The low positive predictive value in this study correlated to high false positive in this study (19.59%) due to patients without malignancy but had CA-125 levels above 35 U/mL. Negative predictive value was the probability that there was not a disease 17 in a negative result. Negative predictive value of 48% showed that in patients with CA-125 level under or equal to 35 U/mL, only 48% of them did not have ovarian malignancy. High false negative and low true negative in this study could cause low negative predictive level. False negative in CA-125 in most cases attributed to the small volume of tumors, therefore minimal tumor volume is needed to obtain 18 CA-125 level elevation. Diagnostic method centers in concepts that the tumor will release a certain 4 specific cell surface antigen determinant. Small volume tumors with fewer cells will express less CA-125 than tumors with larger volume. Criteria of samples in this study were not explicit in stage, grade, or size of the tumor so findings may vary in patients in this study. Diagnostic accuracy correlated with test ability to distinguish between target conditions, in this study, it was between ovarian epithelial malignancy and without one. The discriminatory potential of accuracy can be measured by sensitivity, specificity, predictive value, 19 and area under the ROC curve. The accuracy of CA-125 in this study is 67.01%, almost equal to the overall accuracy of 67% in al iterature review by 18 Jacobs and Bast. 
CONCLUSION AND SUGGESTION
This study found CA-125 diagnostic value as follows: sensitivity of 80.30%, specificity of 38.71%, the positive predictive value of 73.61%, the negative predictive value of 48%, and accuracy of 67.01%. CA-125 is high in sensitivity but low in specificity among epithelial ovarian cancer patients in the Dr. Soetomo Hospital Surabaya in 2016. A similar study in the future is suggested to use cohort design with the primary data source.
